Kodai Capital Management LP Purchases Shares of 21,159 Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Kodai Capital Management LP purchased 21,159 shares of Alnylam Pharmaceuticals valued at approximately $5.7 million, marking a new stake during the first quarter.
• Alnylam Pharmaceuticals reported an EPS of $0.32 for the last quarter, significantly beating analysts' expectations, and its quarterly revenue rose 17.3% year-over-year, totaling $773.69 million.
• Institutional investors own 92.97% of Alnylam's stock, with several hedge funds, including Vanguard and GAMMA Investing, significantly increasing their stakes in the company recently.

Kodai Capital Management LP acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,159 shares of the biopharmaceutical company's stock, valued at approximately $5,713,000.

Other institutional investors also recently made changes to their positions in the company. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $27,000. Whipplewood Advisors LLC lifted its position in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. lifted its position in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares during the period. Park Square Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth approximately $28,000. Finally, Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth approximately $35,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.4%

NASDAQ:ALNY traded down $2.00 during trading hours on Wednesday, hitting $445.00. 586,575 shares of the stock traded hands, compared to its average volume of 957,030. The firm has a 50 day moving average price of $379.67 and a 200 day moving average price of $305.57. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $469.81. The firm has a market cap of $58.33 billion, a price-to-earnings ratio of -180.12 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the prior year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ALNY shares. Jefferies Financial Group increased their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research report on Monday, July 7th. UBS Group increased their price objective on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Truist Financial started coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 price objective for the company. Bank of America increased their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Finally, JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $412.79.

Insiders Place Their Bets

In other news, EVP Pushkal Garg sold 1,455 shares of the company's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the transaction, the executive vice president directly owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. This represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the company's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director directly owned 911 shares in the company, valued at $397,724.38. This trade represents a 97.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock valued at $25,551,456 in the last three months. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.